Evidence map›Paper›PMID 36383245›Full record

ArticleCancer immunology, immunotherapy : CII2023

Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade.

Aditya Jain, Shijia Zhang, Ryan M Shanley, Naomi Fujioka, Robert A Kratzke, Manish R Patel, Amit A Kulkarni

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aditya JainDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Shijia ZhangDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Ryan M ShanleyBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Naomi FujiokaDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Robert A KratzkeDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Manish R PatelDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Amit A KulkarniDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA. kulkarni@umn.edu.
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

backgroundWe investigated the association of body mass index (BMI) modeled as a continuous variable with survival outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI).

methodsWe performed a single-institution retrospective analysis of consecutively diagnosed locally advanced or metastatic NSCLC patients treated with single-agent ICI in the first line or recurrent setting. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS) and objective response rate (ORR). BMI was modeled using a four-knot restricted cubic spline. Multiple Cox regression was used for survival analysis.

resultsTwo hundred patients were included (female 54%; never smoker 12%). Adenocarcinoma was the most common histology (61%). Median age was 67 years, median BMI was 25.9 kg/m

conclusionWe observed a nonlinear association between BMI and OS following treatment with ICI in advanced NSCLC. Risk of death increases at both extremes of BMI with a nadir that exists around 30 kg/m

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedBody Mass IndexFemaleHumansImmune Checkpoint InhibitorsRetrospective StudiesImmune Checkpoint InhibitorsBMIImmune checkpoint inhibitorsNonlinearityNon-small cell lung cancerOverall survival

Identifiers

PMID36383245
PMCPMC10992579
OpenAlexW4309162818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.